Navco Pharmaceuticals Inc.
NAV.V
TSX
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -96.43% | -96.73% | -46.05% | -51.45% | -18.54% |
| Depreciation & Amortization | -97.09% | -95.97% | -144.98% | -105.20% | -46.75% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -96.44% | -96.71% | -51.26% | -53.08% | -19.29% |
| Operating Income | 96.44% | 96.71% | 51.26% | 53.08% | 19.29% |
| Income Before Tax | 95.00% | 95.50% | -280.45% | 60.12% | 37.75% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 95.00% | 95.50% | -280.45% | 60.12% | 37.75% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 95.00% | 95.50% | -280.45% | 60.12% | 37.75% |
| EBIT | 96.44% | 96.71% | 51.26% | 53.08% | 19.29% |
| EBITDA | 99.46% | 99.13% | 51.14% | 54.65% | 21.53% |
| EPS Basic | 95.31% | 96.27% | -198.32% | 70.74% | 56.56% |
| Normalized Basic EPS | 95.54% | 95.77% | 61.76% | 64.09% | 44.00% |
| EPS Diluted | 95.31% | 96.27% | -198.32% | 70.74% | 56.56% |
| Normalized Diluted EPS | 95.54% | 95.77% | 61.76% | 64.09% | 44.00% |
| Average Basic Shares Outstanding | 2.22% | 10.49% | 20.26% | 29.69% | 64.75% |
| Average Diluted Shares Outstanding | 2.22% | 10.49% | 20.26% | 29.69% | 64.75% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |